Xcout IntelAcumen Pharmaceuticals, Inc. competitors & alternatives
The 12 closest competitors and alternatives to Acumen Pharmaceuticals, Inc. among biotech companies — ranked by similarity to what Acumen Pharmaceuticals, Inc. actually does, not by market-cap band.
Subscribe to see Acumen Pharmaceuticals, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals Inc. operates as a biopharmaceutical entity in the clinical development stage, dedicated to discovering and advancing therapeutic solutions for Alzheimer's disease. A key focus for the company involves progressing ACU193, an investigational targeted immunotherapy drug candidate. This particular humanized monoclonal antibody is currently undergoing initial human testing in Phase I clinical trials, where it is designed to specifically target soluble amyloid-beta oligomers. The firm was established in 1996 and maintains its principal headquarters in Charlottesville, Virginia.
Acumen Pharmaceuticals, Inc. at a glance
Acumen Pharmaceuticals, Inc. is a biotech company headquartered in Newton, United States. It is publicly listed (ABOS) with a market capitalisation of $192.1M. Xcout tracks 19 named people at Acumen Pharmaceuticals, Inc., including Daniel J. O'Connell (Chief Executive Officer & Director).
Acumen Pharmaceuticals, Inc. leadership
- Daniel J. O'ConnellChief Executive Officer & Director
- James DohertyPresident & Chief Development Officer
- Russell BartonChief Operating Officer
- Matt ZugaChief Financial Officer & Chief Business Officer
- Derek MeisnerChief Legal Officer & Corporate Secretary
- Caleb E. FinchCo-Founder
13 more named people on record for Acumen Pharmaceuticals, Inc., with roles, board committees and tenure — see the full roster →
Top 12 Acumen Pharmaceuticals, Inc. competitors
Ranked by semantic similarity — how close each company is to Acumen Pharmaceuticals, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotechnology
Alzheon, Inc. is a clinical-stage biopharmaceutical company headquartered in Framingham, Massachusetts. Founded in 2013, the company is dedicated to developing a broad portfolio of investigational therapeutic products for neurodegenerative disorders, including Alzheimer's disease. Its research centers on advancing disease-modifying treatments for patients with cognitive decline.
Biotechnology
Acadia Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.
Similar biotech company
ProMIS Neurosciences, Inc. is a Canadian biotechnology firm dedicated to creating targeted therapeutic solutions for debilitating neurodegenerative conditions such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company leverages a unique computational discovery platform, utilizing its ProMIS and Collective Coordinates algorithms, to identify novel, disease-specific targets – known as epitopes – located on the surface of misfolded proteins. Its pipeline features several promising drug candidates, including PMN310, a monoclonal antibody designed to address toxic oligomers implicated in Alzheimer's disease. Another candidate, PMN267, targets superoxide dismutase 1 and TAR-DNA binding protein 43 in ALS, and alpha-synuclein associated with Parkinson's disease and Lewy body dementia. Finally, PMN442 is a monoclonal antibody aimed at toxic alpha-synuclein oligomers and seeding fibrils relevant to multiple system atrophy. Established in 2004, the company changed its name from Amorfix Life Sciences Ltd. to ProMIS Neurosciences, Inc. in July 2015. Its corporate headquarters are situated in Toronto, Canada.
Biotechnology
Navion Neurosciences, Inc. is a preclinical-stage biotechnology company located in Charlottesville, Virginia, that is developing next-generation, AI-enabled therapies.
Biotechnology
Muna Therapeutics is a privately held biopharmaceutical company founded in 2020 with headquarters in Copenhagen, Denmark, and operations in Leuven. The company discovers and develops novel therapies aimed at slowing or stopping devastating neurodegenerative diseases like Alzheimer's and Parkinson's.
Biotechnology
CuraSen Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops novel therapies to treat neurodegenerative diseases by targeting specific receptor systems in the brain. The company's scientific approach focuses on restoring neurovascular and neuronal function to serve patients suffering from conditions such as Parkinson's disease and other neurodegenerative disorders.
Similar biotech company
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Biotechnology
Avraham Pharmaceuticals Ltd. is a biotechnology company headquartered in Yavneh, Israel, founded in 2010. The company develops novel small molecule drugs and multi-functional drug substances, such as ladostigil, aimed at the treatment and prevention of neurodegenerative disorders and mild cognitive impairment.
Biotechnology
Adial Pharmaceuticals, Inc. is a biopharmaceutical enterprise operating at the clinical stage, dedicated to researching and developing innovative therapeutic options for the management and prevention of addiction and associated disorders. Its primary investigational compound, AD04, functions as a selective serotonin-3 antagonist and is currently undergoing pivotal Phase III clinical trials for the treatment of alcohol use disorder. Beyond this flagship product, the company is also exploring drug candidates aimed at providing non-opioid pain relief and addressing a range of other medical conditions. Established in 2010, Adial Pharmaceuticals, Inc. is headquartered in Charlottesville, Virginia.
Similar biotech company
Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.
Similar biotech company
Vaccinex, Inc. is a biotechnology firm operating in the clinical stage, dedicated to identifying and developing specialized biological therapies. Its core mission is to address serious medical conditions and diseases that currently lack adequate treatment options. The company's therapeutic endeavors encompass a broad spectrum of illnesses, including various forms of cancer, neurodegenerative disorders, and autoimmune diseases. At the forefront of its pipeline is pepinemab, a humanized monoclonal antibody. This leading candidate has either concluded or is scheduled for Phase 1b/2 clinical investigations, exploring its efficacy against non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alzheimer's disease, osteosarcoma, and melanoma. Furthermore, Vaccinex is progressing with VX5, a human antibody targeting CXCL13, which is presently in preclinical assessment for potential application in multiple sclerosis (MS) and other autoimmune conditions. The company was established in 2001 and has its principal operations located in Rochester, New York.
Life Sciences
EXCIVA GmbH is a privately held biotechnology company established in 2016 in Heidelberg, Germany, focused on developing clinical-stage therapeutics to improve quality of life and treat Alzheimer's disease.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Acumen Pharmaceuticals, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Acumen Pharmaceuticals, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →